Clinical Trial Update: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of LY3300054, an anti-PD-L1 antibody, given alone or in combination in adults with advanced refractory solid tumors, including MSI-H solid tumors,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer Hr-positive
• Cutaneous Melanoma
• Microsatellite Instability-high Solid Tumors
• Pancreatic Cancer

Drugs mentioned

• LY3300054 (anti-PD-L1 antibody)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors | Phase 1 | Status: COMPLETED